Altogether, our data and previously published data on serglycin, EMT, and cancer, may imply that serglycin participates in an immune cell-cancer cell crosstalk, acting as a regulatory molecule that links inflammation and induced oncogenic signaling and EMT in breast cancer cell (Figure 5). Here, SRGN is linked to cancer.